Solid Tumor Targeting CAR-T Development Service with SUPRA CAR System

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

The SUPRA CAR system is a modular platform that decouples antigen recognition from T cell signaling, enabling flexible and tunable targeting of diverse tumor antigens. Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with SUPRA CAR System offers end-to-end solutions for designing, building, and validating next-generation CAR-T therapies tailored to complex solid tumors. Our approach provides superior controllability, multiplexed antigen targeting, and reduced on-target/off-tumor toxicity, key advantages for overcoming heterogeneous and immunosuppressive tumor microenvironments.

Introduction

The SUPRA (Split, Universal, and Programmable) CAR is a modular chimeric antigen receptor system composed of two separate components: a universal signaling receptor (zipCAR) expressed on T cells and a soluble antigen-binding module (zipFv). By decoupling antigen recognition from T cell activation, the SUPRA CAR system introduces an unprecedented level of flexibility, controllability, and safety into CAR-T therapy, enabling dynamic targeting of multiple antigens, tunable activation strength to mitigate toxicity, and the capacity to counteract tumor antigen escape, thereby representing a pivotal advancement toward programmable and precision cancer immunotherapy.

Fig.1 Structural design of the split universal programmable CAR. (Creative Biolabs Original) Fig.1 The SUPRA CAR system composition.

Solid Tumor Targeting CAR-T Development Service with SUPRA CAR System at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with SUPRA CAR System leverages the innovative SUPRA CAR system to overcome key challenges in allogeneic cell therapy. We provide end-to-end solutions, from design to functional validation, enabling logic-gated, multiplexed targeting of heterogeneous solid tumors while minimizing on-target/off-tumor toxicity. Our platform ensures enhanced specificity, scalable production, and clinically relevant activity against complex TME.

What We Can Offer

Our service provides end-to-end solutions for solid tumor CAR-T development using the SUPRA CAR platform, encompassing customized zipCAR design, comprehensive zipFv library screening, rigorous functional validation of combination strategies, and optimized treatment regimens to achieve potent, tunable anti-tumor activity with enhanced safety.

Featured services of solid tumor targeting CAR-T development service with SUPRA CAR system. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target Antigen Data.
Patient-Derived Xenograft (PDX) Models (for functional validation).
Pre-Screened ScFv sequences (optional).

Key steps:

Workflow of solid tumor targeting CAR-T development service with SUPRA CAR system. (Creative Biolabs Original)

Final Deliverables:

Comprehensive SUPRA-CAR Construct Report.
Functional Assays Data.
Allogeneic T Cell Master Bank.

Key Advantages

Fully Customizable SUPRA CAR Logic Circuits: We offer tailored synthetic design services to optimize the modular binding and signaling domains, meeting unique solid tumor heterogeneity challenges, ensuring optimal target affinity and activation control.
Scalable Allogeneic Master Bank Production: Access to high-capacity T cell expansion and banking utilizing advanced modular production suites, guaranteeing unmatched "off-the-shelf" scalability and supply security.

FAQ

How does the SUPRA system improve safety compared to standard CAR-T cells?

Standard CARs often cause high-grade cytokine release syndrome (CRS) due to uncontrolled activation. The SUPRA system is "split" and requires an adaptor molecule to bridge the T cell receptor to the antigen. Crucially, the system allows for logic-gating, meaning the T cell can be programmed to activate only when two or more specific antigens are present, drastically minimizing on-target, off-tumor toxicity.

Can the SUPRA system help combat tumor antigen escape and heterogeneity?

Absolutely. Tumor heterogeneity and subsequent antigen loss are primary causes of relapse. The universal design allows the targeting module to be easily swapped or multiplexed to sense several different tumor antigens simultaneously. This built-in adaptability means the CAR-T cell is less likely to lose its target, maintaining durable efficacy even as the tumor evolves.

Why Choose Us?

Creative Biolabs pioneers the integration of advanced synthetic biology into cell therapy, accelerating the translation of next-generation universal CAR platforms into actionable treatments. Leveraging two decades of specialized experience, our technology is strategically designed to address the persistent obstacles in solid tumor targeting and streamline CAR-T development processes.

Customer Reviews

"Using Creative Biolabs' SUPRA CAR System in our solid tumor research has significantly improved the ability to differentiate between highly homologous tumor and healthy tissue antigens. The level of safety tuning is unparalleled." Dr. S***n Smith.

"We previously struggled with antigen escape in our glioblastoma models. The multiplexed targeting feature of the SUPRA platform provided by Creative Biolabs is a game-changer; it ensures dual-antigen recognition and maintains persistent killing even after the loss of one target." Prof. Bn Lee.

How to Contact Us?

Built upon the strategic convergence of allogeneic scalability and precise synthetic control, Creative Biolabs offers a cutting-edge platform for developing potent yet safe solid tumor-targeting CAR-T cell therapies via the SUPRA CAR system.

Partner with us to advance your next-generation immunotherapy project.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.